Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH
• Collaborator: Sanofi
• Treatments: Insulin; Insulin Glargine

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit not previously treated with glitazones, insulin or GLP-1 agonists

• Inadequately controlled diabetes mellitus

Exclusion Criteria:

• Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis